# A Study of RAY1225 in Participants With Type 2 Diabetes

> **NCT06254274** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 210 (actual)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** RAY1225
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06254274
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-26
- **Primary completion:** 2025-12-20
- **Final completion:** 2025-12-20
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254274, "A Study of RAY1225 in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06254274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*